"Cyclopropanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
| Descriptor ID |
D003521
|
| MeSH Number(s) |
D02.455.426.392.368.533
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclopropanes".
Below are MeSH descriptors whose meaning is more specific than "Cyclopropanes".
This graph shows the total number of publications written about "Cyclopropanes" by people in this website by year, and whether "Cyclopropanes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 3 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 6 | 7 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 5 | 6 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 4 | 0 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 4 | 0 | 4 |
| 2025 | 1 | 1 | 2 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclopropanes" by people in Profiles.
-
Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies. Eur J Clin Invest. 2026 Oct; 56(10):e70256.
-
Comparative adjuvant therapy to reduce vancomycin-associated nephrotoxicity in an animal model. Antimicrob Agents Chemother. 2026 Oct 07; 70(10):e0088726.
-
Dolutegravir Is Associated With Lower Odds of Gestational Diabetes Compared to Other Antiretroviral Therapy Regimens Among Pregnant Women in India: A Cross-Sectional Analysis. J Int AIDS Soc. 2026 Sep; 29(9):e70200.
-
Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. J Infect Dis. 2025 Jul 30; 232(1):191-198.
-
Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV. AIDS. 2024 07 15; 38(9):1439-1442.
-
Insights into E. coli Cyclopropane Fatty Acid Synthase (CFAS) Towards Enantioselective Carbene Free Biocatalytic Cyclopropanation. Angew Chem Int Ed Engl. 2024 07 15; 63(29):e202403493.
-
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data. Mult Scler. 2024 May; 30(6):696-706.
-
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. Ann Hepatol. 2023 Mar-Apr; 28(2):100899.
-
Montelukast as an effective adjuvant in the treatment of moderate acne vulgaris. Dermatol Ther. 2022 10; 35(10):e15770.
-
Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.